Molecular determinants of response to PD-L1 blockade across tumor types

Molecular determinants of response to PD-L1 blockade across tumor types

PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Romain Banchereau, Ning Leng, Oliver Zill, Ethan Sokol, Gengbo Liu, Dean Pavlick, Sophia Maund, Li-Fen Liu, Edward Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe June Assaf, Daniel Bower, Namrata Patil, Mark McCleland, David Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti Hegde, Thomas Powles
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/ae29efdfced64f11b4172bdb2e1a8bde
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/ae29efdfced64f11b4172bdb2e1a8bde

Ejemplares similares